8-K: Zenas BioPharma Unveils Strategic Vision and Clinical Milestones for Obexelimab in Autoimmune Diseases

Zenas BioPharma, Inc. presented its corporate strategy and clinical pipeline for Obexelimab, a B cell inhibitor, targeting multi-billion dollar markets in IgG4-Related Disease, Relapsing Multiple Sclerosis, and Systemic Lupus Erythematosus, with significant Phase 2 and Phase 3 data expected through mid-2026.

Summary

• Zenas BioPharma, Inc. is furnishing an investor presentation (Exhibit 99.1) for the Jefferies Global Healthcare Conference on June 5, 2025, and investor/analyst meetings on June 4-5, 2025.
• The company is focused on developing Obexelimab, a first-in-class bifunctional B cell targeting (CD19 x FcγRIIb) antibody, for autoimmune diseases.
• Obexelimab is currently in a Phase 3 trial for IgG4-Related Disease (IgG4-RD) and randomized Phase 2 trials for Relapsing Multiple Sclerosis (RMS) and Systemic Lupus Erythematosus (SLE).
• The company estimates these indications represent a potential multi-billion-dollar commercial opportunity.
• Zenas BioPharma reported approximately $314 million in cash as of Q1 2025, providing funding into Q4 2026 through meaningful Phase 3 and Phase 2 readouts.
• Key upcoming data readouts include Phase 3 topline results for the INDIGO trial in IgG4-RD around year-end 2025, primary endpoint data for the Phase 2 MoonStone trial in RMS early Q4 2025, and primary endpoint data for the Phase 2 SunStone trial in SLE mid-2026.
• Obexelimab's mechanism of action involves co-engagement of CD19 and FcγRIIb, leading to an inhibitory effect on B cells rather than direct depletion, and is engineered to avoid ADCC/CDC-mediated depletion.
• Previous clinical trials demonstrated Obexelimab's activity, including rapid and sustained reduction in IgG4-RD disease activity in a Phase 2 trial, where 100% of patients met the primary endpoint and 93% had an ongoing response at the end of the trial.
• The Phase 3 INDIGO trial for IgG4-RD is the largest ever conducted for the disease, with over 190 patients, and its design is substantially similar to the MITIGATE trial (Uplizna), which showed an 87% reduction in IgG4-RD flare risk.
• The estimated U.S. market opportunity for IgG4-RD is approximately $3 billion at orphan pricing, with a diagnosed prevalence of around 20,000 patients.
• The company's executive team has extensive experience, collectively contributing to over 70 IND filings, 30 BLA/NDA filings, and 30 commercial product launches.

Sentiment

Score: 9

Explanation: The document presents a highly positive outlook, emphasizing a strong cash position, multiple advanced clinical programs targeting large markets, a differentiated mechanism of action, and an experienced management team. The upcoming data readouts are significant catalysts, and prior clinical results are presented favorably. The risks mentioned are standard for a biopharmaceutical company at this stage.

Positives

• Zenas BioPharma is well-funded with approximately $314 million in cash as of Q1 2025, providing a runway into Q4 2026, covering key clinical data readouts.
• Obexelimab is a potentially first-in-class bifunctional B cell targeting antibody with a differentiated non-depleting mechanism, which could offer a significant advantage in autoimmune disease treatment.
• The company has multiple clinical programs in advanced stages, including a Phase 3 trial in IgG4-RD and two Phase 2 trials in RMS and SLE, addressing large, multi-billion dollar market opportunities.
• Prior clinical data for Obexelimab in IgG4-RD demonstrated rapid, robust, and sustained reduction in disease activity, with 100% of patients meeting the primary endpoint in a Phase 2 trial.
• The Phase 3 INDIGO trial for IgG4-RD is the largest ever conducted for the disease, and the positive results from the similarly designed MITIGATE trial de-risk the INDIGO assumptions.
• The company has an experienced executive team with a strong track record of successful product development, regulatory approvals, and commercial launches.
• Obexelimab's subcutaneous formulation offers convenience for patients, potentially enhancing market adoption.

Negatives

• The company has a limited operating history and has incurred substantial losses since its inception, with anticipation of incurring substantial and increasing losses for the foreseeable future.
• Clinical development is inherently lengthy, expensive, and characterized by uncertain outcomes, with risks of additional costs or delays.
• The company will need substantial additional financing to achieve its long-term goals beyond the current funding runway.

Risks

• The company has a limited operating history and has incurred substantial losses since its inception, anticipating substantial and increasing losses for the foreseeable future.
• There is a need for substantial additional financing to achieve the company's goals.
• The uncertainty of clinical development, which is lengthy and expensive, is characterized by uncertain outcomes and risks related to additional costs or delays in completing, or failing to complete, the development and commercialization of current or future product candidates.
• Delays or difficulties in the enrollment and dosing of patients in clinical trials could occur.
• There is a risk of significant adverse events or undesirable side effects caused by the company's product candidates.
• Potential competition exists from large and specialty pharmaceutical and biotechnology companies, many of which already have approved therapies in the company's current indications.
• The company's ability to realize the benefits of current or future collaborations or licensing arrangements and its ability to successfully consummate future partnerships is uncertain.
• There is a risk that the company may not obtain regulatory approval to commercialize any product candidate in the United States or any other jurisdiction, or that any such approval may be for a more narrow indication than sought.

Future Outlook

Zenas BioPharma anticipates significant clinical milestones with Phase 3 topline results for the INDIGO trial in IgG4-RD expected around year-end 2025, Phase 2 primary endpoint data for the MoonStone trial in RMS expected early Q4 2025, and Phase 2 primary endpoint data for the SunStone trial in SLE expected mid-2026. The company projects Obexelimab to be a multi-billion dollar franchise molecule across its target autoimmune indications, with a U.S. market opportunity of approximately $3 billion for IgG4-RD alone.

Management Comments

• The company is focused on 'Enabling patients with autoimmune diseases to reimagine life' through its innovative pipeline.
• Management highlights Obexelimab as a 'potentially highly differentiated I&I franchise molecule' with 'multiple upcoming Phase 2 and Phase 3 data readouts'.
• The company is 'well-funded into Q4:26 through meaningful Phase 3 and Phase 2 readouts', demonstrating financial stability for upcoming catalysts.
• The executive team emphasizes their 'established global development and regulatory capabilities' and a 'history of successful product approvals and commercial launches'.

Industry Context

The document positions Obexelimab within the rapidly evolving landscape of autoimmune disease treatments, particularly B cell-targeted therapies. It highlights the significant unmet need in conditions like IgG4-RD, RMS, and SLE, which represent multi-billion dollar markets. The non-depleting mechanism of Obexelimab is presented as a differentiated approach compared to existing B cell depleting therapies, potentially offering a safer and more convenient option (subcutaneous dosing). The company aims to capitalize on the validated role of B cells in these diseases, building on the success of other B cell therapies in the market.

Comparison to Industry Standards

• Obexelimab's Phase 2 IgG4-RD trial results showed 100% of patients meeting the primary endpoint and 93% with ongoing response, with 80% of rituximab-experienced patients achieving complete remission, suggesting strong efficacy compared to existing treatments.
• The Phase 3 INDIGO trial design for Obexelimab in IgG4-RD is noted as 'substantially similar' to the MITIGATE trial for Uplizna (inebilizumab), which demonstrated an 87% reduction in IgG4-RD flare risk at 52 weeks, providing a positive benchmark and de-risking event for INDIGO's assumptions.
• In the context of Multiple Sclerosis, MoonStone's key inclusion/exclusion criteria are similar to previous Phase 2 B cell-directed programs like ocrelizumab, ofatumumab, ublituximab, tolebrutinib, frexalimab, and fenebrutinib, allowing for direct comparison of efficacy metrics like mean new Gd+ T1 lesions (e.g., frexalimab at 0.2 and fenebrutinib at 0.03 at week 12).
• For SLE, the previous Phase 2 trial for Obexelimab showed higher clinical activity (35% with optimized exposure, 52% in biomarker positive population) compared to the modest effect sizes of 12-17% over placebo demonstrated by current approved therapies on SRI-4/BICLA assessments.

Stakeholder Impact

• Shareholders: Potential for significant value appreciation driven by upcoming clinical data readouts and the large market opportunities for Obexelimab.
• Patients: Development of a potentially differentiated, non-depleting B cell therapy could offer new and improved treatment options for debilitating autoimmune diseases like IgG4-RD, MS, and SLE.
• Employees: The company's strong financial position and clear development pipeline provide stability and growth opportunities.
• Investors: The document highlights a compelling investment opportunity with multiple near-term catalysts and a long-term vision for a multi-billion dollar franchise.

Next Steps

• Management presentation at the Jefferies Global Healthcare Conference on June 5, 2025.
• Meetings with investors and analysts at the Jefferies Global Healthcare Conference on June 4-5, 2025.
• Topline results from the Phase 3 INDIGO trial in IgG4-RD expected around year-end 2025.
• Primary endpoint (12-week) data from the Phase 2 MoonStone trial in RMS expected early Q4 2025.
• Primary endpoint (24-week) data from the Phase 2 SunStone trial in SLE expected mid-2026.
• Potential progression to Phase 3 trials for Obexelimab in RMS (including nrSPMS and PPMS) following MoonStone data.

Key Dates

Recommendation

Keywords

Zenas BioPharma, Obexelimab, Autoimmune Diseases, IgG4-Related Disease, Relapsing Multiple Sclerosis, Systemic Lupus Erythematosus, Biotechnology, Clinical Trials, Phase 3, Phase 2, B cell inhibitor, CD19, FcγRIIb, Immunology, Orphan Drug, Nasdaq